Zyban (Bupropion)

What is Zyban?

Zyban (bupropion hydrochloride) is a prescription-only medicine described here using the UK Zyban 150 mg prolonged-release product information for smoking cessation in adults. This is not a central EMA authorisation or proof of Spanish availability. It is an antidepressant — specifically an aminoketone class antidepressant — that was initially developed and used under the name Wellbutrin for treating depression, before being approved in a modified formulation specifically for smoking cessation.

Crucially, Zyban contains no nicotine. It works through an entirely different mechanism from nicotine replacement therapy (NRT), acting on the brain’s reward and motivational pathways to reduce the drive to smoke.

How does Zyban work?

Bupropion’s mechanism of action in smoking cessation is not fully elucidated, but is understood to involve:

• Inhibition of dopamine reuptake: Bupropion blocks the reuptake of dopamine in the nucleus accumbens and other reward-related brain regions, partially compensating for the dopaminergic reward that nicotine provides. This may reduce the reinforcing effects of smoking and diminish cravings.
• Inhibition of noradrenaline (norepinephrine) reuptake: Noradrenergic effects may help manage nicotine withdrawal symptoms including irritability, anxiety, and difficulty concentrating.
• Weak nicotinic receptor antagonism: Some evidence suggests bupropion may also have a limited direct effect on nicotinic receptors, though this is considered a secondary mechanism.

The overall effect is a reduction in the urge to smoke and attenuation of withdrawal symptoms — without delivering nicotine or acting primarily through nicotine receptors (unlike Champix/varenicline).

Who is Zyban for?

Zyban is indicated for adult smokers who are motivated to stop smoking. It may be particularly appropriate for:

• Smokers who prefer a non-nicotine pharmacological approach
• Those who have not responded adequately to NRT alone
• Adults whose history and preferences support its use after individual assessment; depressive symptoms require assessment and monitoring
• Those who cannot tolerate varenicline (Champix) due to gastrointestinal side effects

Zyban is contraindicated in patients with:

• A current or prior history of seizures (any seizure disorder)
• A current or prior history of eating disorders (anorexia nervosa, bulimia nervosa)
• History of bipolar disorder
• Severe hepatic cirrhosis
• Concomitant MAOIs: allow at least 14 days after stopping an irreversible MAOI, or 24 hours after a reversible MAOI, before starting Zyban
• Abrupt discontinuation of alcohol, benzodiazepines or other medicines whose withdrawal increases seizure risk
• A CNS tumour
• Allergy to bupropion or an excipient
• Taking any other medicine containing bupropion

Zyban requires careful consideration and close monitoring in patients with:

• A history of depression or other psychiatric conditions
• Cardiovascular disease
• Liver or kidney impairment

Dosage

Zyban is started before the patient stops smoking, to allow therapeutic blood levels to develop.

Key rules:

• Never exceed 150 mg per dose or 300 mg per day
• Ensure at least 8 hours between doses (twice daily dosing)
• Do not crush, chew, or halve the tablets
• Set a quit date in the first two weeks of treatment, preferably the second week
• Total treatment is 7–9 weeks including the initial six days; stop if there is no effect by 7 weeks
• Older adults and patients with renal impairment or mild–moderate hepatic impairment: 150 mg once daily, with monitoring. Severe hepatic cirrhosis is contraindicated
• Use under 18 years is not recommended

Side effects

Very common side effects

• Insomnia: One of the most frequently reported side effects; avoiding a bedtime dose can help, while always leaving at least 8 hours between doses

Common side effects

• Dry mouth

• Headache

• Nausea

• Dizziness

• Agitation or anxiety

• Tremor

• Constipation

• Skin reactions including rash or itching

Uncommon side effects

• Elevated blood pressure

Serious risks

• Seizures: The most clinically significant safety concern. The risk is approximately 1 in 1,000 at the recommended doses; higher with dose escalation or in patients with predisposing factors. Zyban must be stopped immediately if a seizure occurs and must not be restarted.
• Neuropsychiatric effects: Changes in mood, behaviour, or thinking — including depression, suicidal ideation, hostility, and agitation — have been reported. These may be related to nicotine withdrawal, the medicine, or both.
• Hypersensitivity reactions: Including severe rash (Stevens-Johnson syndrome, rarely). Stop Zyban and seek medical attention for any serious skin reaction; do not restart after a severe reaction.
• Hypertension: Check blood pressure before treatment and monitor during treatment; weekly monitoring is recommended when combined with nicotine patches. This is a combination precaution, not an instruction to stop another medicine.

Zyban vs alternatives

Champix (varenicline) generally shows higher quit rates in head-to-head studies with bupropion. However, Zyban may be preferred where varenicline is not tolerated or is contraindicated. The decision should be made with a prescribing doctor.

How to access Zyban online in Europe

Zyban is prescription-only under the cited UK label. Other bupropion brands or national authorisations do not establish interchangeable smoking-cessation products. It cannot be dispensed without a valid prescription from a qualified medical professional.

Prescrivia operates as a technology intermediary, connecting patients with independent doctors for online health assessments. We do not prescribe medicines, employ doctors, or sell medicines directly. If an independent doctor determines that bupropion is clinically appropriate following a thorough assessment, they may issue a prescription, with dispensing the responsibility of a licensed pharmacy under applicable national rules.

Important: Prescrivia does not guarantee that a prescription will be issued. All clinical decisions are made independently by qualified medical professionals, particularly given Zyban’s important contraindications.

Important safety information

Stop Zyban and seek immediate medical attention if you experience:

• A seizure or convulsion
• Severe skin reaction (rash with blistering or peeling)
• Significant mood changes, suicidal thoughts, or unusual behaviour

Do not take Zyban if you:

• Have a history of seizures or eating disorders
• Are taking MAOIs; the washout intervals above must be respected
• Are drinking large amounts of alcohol or using benzodiazepines and plan to stop abruptly

Other precautions: Discuss all medicines, particularly serotonergic antidepressants, medicines that lower the seizure threshold and tamoxifen. Serotonin syndrome has been reported with serotonergic combinations. Discuss Brugada syndrome or family history of sudden cardiac death. Zyban should not be used during pregnancy; breastfeeding requires an individual benefit/risk decision. Do not drive until you know how it affects you.

Alcohol: Zyban may lower seizure threshold; excessive alcohol consumption further increases this risk. Alcohol should be minimised or avoided during treatment.

In Spain, distance sale of prescription medicines is prohibited under Article 3.5 of Royal Legislative Decree 1/2015. An online assessment does not remove this restriction. Dispensing and access depend on the exact product and applicable national rules.

Sources

Medical information on this page is based on the following sources:

• GSK: UK Zyban 150 mg prolonged-release tablets, sections 4.1–4.8 and 5.1.
• WHO: tobacco cessation guideline, section 3.3.

This overview does not replace the full product information. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.